雪榕生物(300511) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥842,411,282.63, representing a 46.27% increase compared to ¥575,916,010.18 in the same period last year[6] - Net profit attributable to shareholders was ¥222,710,908.61, a significant increase of 288.02% from ¥57,397,068.93 year-on-year[6] - The net cash flow from operating activities surged by 715.55% to ¥295,287,662.74, compared to ¥36,207,316.24 in the previous year[6] - Basic earnings per share increased to ¥0.45, up 246.15% from ¥0.13 in the same period last year[6] - Operating profit surged to ¥233,488,096.74, up 311.5% from ¥56,800,357.57 year-over-year[25] - Total comprehensive income for the period was ¥233,334,584.76, compared to ¥60,304,994.90 in the same quarter last year[26] - The company reported a net profit of approximately 565.11 million CNY in Q1 2023, compared to 342.40 million CNY at the beginning of the year, reflecting strong profitability growth[23] Asset and Equity Growth - Total assets at the end of the reporting period were ¥4,250,354,252.97, reflecting a 4.38% increase from ¥4,072,032,071.35 at the end of the previous year[6] - As of the end of Q1 2023, the company's total assets reached approximately 4.25 billion CNY, an increase from 4.07 billion CNY at the beginning of the year[22] - The company's total equity increased to approximately 1.87 billion CNY from 1.63 billion CNY at the beginning of the year, showing growth in shareholder value[23] Cash Flow and Liquidity - Cash flow from operating activities generated ¥295,287,662.74, compared to ¥36,207,316.24 in the previous year, marking a substantial improvement[29] - The company reported a net cash inflow from investment activities of ¥148,277,051.27, reversing a net outflow of ¥102,660,123.39 in the prior period[29] - The company's cash and cash equivalents increased to approximately 700.87 million CNY from 363.82 million CNY at the beginning of the year, reflecting a significant liquidity improvement[22] - The cash and cash equivalents at the end of the period totaled ¥693,290,300.17, down from ¥708,021,120.92 at the end of the previous period[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,204[14] - The largest shareholder, Yang Yongping, holds 21.39% of the shares, totaling 107,606,850 shares, with 4,500,000 shares pledged[14] - Zhejiang Yinwan Siter Investment Management Co., Ltd. holds 22,100,000 shares, representing a 4.39% stake[14] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder having a substantial influence[15] - The total number of restricted shares at the beginning of the period was 94,833,144, with no new restrictions added during the reporting period[18] - Yang Yongping's restricted shares remain at 80,705,137, locked due to executive restrictions[17] - The company has no preferred shareholders or related party transactions among the top shareholders[16] - The company is focused on maintaining shareholder stability and has established agreements among major shareholders to ensure coordinated actions[15] - There are no changes in the number of restricted shares for departing directors during this quarter[17] - The company continues to emphasize its commitment to corporate governance and shareholder rights[18] Investment and Expansion - The company established a wholly-owned subsidiary in Guangxi with a total investment of over 650 million CNY for a modern agricultural park project with an annual output of 195,000 tons of edible mushrooms[20] - A new subsidiary was set up in Jiangsu for a project with a total investment of 1.2 billion CNY, including a phase one investment of 1 billion CNY for a daily production of 200 tons of enoki mushrooms and related products[21] - The company has a long-term investment strategy, as evidenced by the establishment of new subsidiaries and significant capital investments in modern agricultural projects[20][21] - The company is focused on expanding its market presence through strategic investments and new product development initiatives[20][21] Cost and Expense Management - The company's total operating costs rose to ¥611,504,827.66, an increase of 16.6% from ¥524,517,329.91 in the previous period[25] - Research and development expenses slightly increased to ¥1,860,518.88 from ¥1,826,764.99, indicating continued investment in innovation[25] - The company experienced a 231.32% increase in sales expenses, totaling ¥16,736,831.36, primarily due to increased personnel costs[12] Return on Investment - The weighted average return on equity rose to 12.00%, an increase of 8.63% from 3.37% in the previous year[6] - Investment income saw a remarkable increase of 968.75%, reaching ¥1,111,314.53 compared to a loss of ¥127,921.46 in the previous year[12]